CSIMarket Company Name, Ticker, Competitors, else..
 
Humacyte Inc   (HUMA)
Other Ticker:  
 
 
Price: $5.2800 $-0.36 -6.383%
Day's High: $5.65 Week Perf: 0.57 %
Day's Low: $ 5.20 30 Day Perf: -14.01 %
Volume (M): 2,241 52 Wk High: $ 9.97
Volume (M$): $ 11,830 52 Wk Avg: $4.36
Open: $5.65 52 Wk Low: $1.96



 Market Capitalization (Millions $) 629
 Shares Outstanding (Millions) 119
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -140
 Cash Flow (TTM) (Millions $) -21
 Capital Exp. (TTM) (Millions $) 1

Humacyte Inc
Humacyte Inc is a biotechnology company that specializes in developing and manufacturing a groundbreaking regenerative medicine platform. The company focuses on the development of universal tissue and blood vessel replacements for patients in need. Their proprietary technology involves growing blood vessels in a lab, using a human cell-based tissue engineering platform. Humacyte's goal is to provide patients with long-lasting, off-the-shelf, and biocompatible blood vessels that can be used in various surgical procedures, such as by-pass surgeries or replacement of damaged blood vessels. Their innovative approach offers potential solutions to disorders requiring vascular access or complex vascular surgeries.


   Company Address: 2525 East North Carolina Highway 54 Durham, 27713 NC
   Company Phone Number: 313-9633   Stock Exchange / Ticker: NASDAQ HUMA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Humacyte Acellular Tissue Engineered Vessel (ATEV) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriov...

Published Wed, Jul 31 2024 11:01 AM UTC

Breakthrough in Hemodialysis: Humacyte's Acellular Tissue Engineered Vessel Outperforms Standard Fistula in Phase 3 TrialIn a significant advancement in the realm of hemodialysis access, Humacyte has unveiled the promising results from its V007 Phase 3 clinical trial, establishing its Acellular Tissue Engineered Vessel (ATEV) as a superior alternative compared to the tradit...
Stocks on the Move

Pioneering Advances in Vascular Solutions Assessing the Impact of Humacyte Inc. on the Pharmaceutical Industry

Published Fri, Jul 19 2024 7:02 PM UTC

In recent years, Humacyte Inc., a clinical-stage biotechnology platform company, has garnered significant attention for its groundbreaking advancements in bioengineered human tissues. This article aims to interpret several recent articles and assess their impact on the pharmaceutical industry, focusing on the performance of Humacyte Inc. shares and its potential as an innova...
Clinical Study

Advancements in BioVascular Pancreas Show Promising Potential for Type 1 Diabetes Treatment

Published Tue, Jun 25 2024 12:00 PM UTC

The development of effective treatments for type 1 diabetes continues to be a significant focus in medical research. Recently, Humacyte presented positive preclinical data showcasing their BioVascular Pancreas (BVP) product candidate as a potential treatment option for individuals with type 1 diabetes. This article aims to provide an overview of the key details and implicat...
Product Service News

Centers for Medicare & Medicaid Services Releases ICD-10-PCS Codes for Humacytes Human Acellular Vessel (HAV)

Published Mon, Jun 17 2024 12:00 PM UTC

The Centers for Medicare & Medicaid Services (CMS) recently announced the issuance of four distinct ICD-10-PCS codes, effective from October 1, 2024. These codes are specifically designated for the replacement of arteries in the upper and lower extremities using Humacytes Human Acellular Vessel (HAV). This development holds significant implications for the field of drug disc...
Humacyte Inc

Humacyte Inc. Hits Milestone with $0.06 Million Revenue in Q1 2024 Financial Report

Humacyte Inc, a clinical-stage biotechnology platform company, has been making waves in the stock market recently with its innovative work in developing universally implantable, bioengineered human tissue at commercial scale. The company has reported some interesting figures regarding its revenue and net shortfall in the fiscal time-frame ending March 31, 2024.
According to the financial report, Humacyte generated $0.06 million in revenue during this period. While this may appear relatively modest in comparison to some other companies, it is important to note that Humacyte is a clinical-stage biotech firm focusing on cutting-edge research and development. The fact that the company has already started generating revenue highlights its progress and potential in the field.






Humacyte Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com